// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Prospective risk of stillbirth according to fetal size at term

O. Hugh - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The impact of a routine 36-week growth scan on the incidence, diagnosis and management of breech presentation

I. Salim - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prenatal identification of poor fetal growth: a systematic review of predictive models in early pregnancy

S. Goni - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

How sensitive are consensus-based definitions of late FGR in the identification of malnourished newborns?

N. Griffiths - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Thresholds for intervention in late onset fetal growth restriction

M.L. Gazet - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Can we justify intervening? A cohort study examining maternal outcomes and scan utility in predicting large for gestational age

B. Simpson - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Abnormal biometric and Doppler markers in pregnancies complicated by pre-existing and gestational diabetes mellitus in the third trimester

P. Iannone - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Gestational Diabetes

N/A

Carbon monoxide monitoring in pregnancy and ultrasound: an audit performed at Bradford Teaching Hospitals to help improve detection of growth-restricted babies

A. Belchita - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Antenatal magnetic resonance imaging of fetal skeletal system

J. Rodger - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

stannous fluoride

Systematic review of methodology used in second and third trimester pregnancy dating using ultrasound and symphysio-fundal height measurements

A. Self - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Assessment of fetal growth: how accurate are we in practice?

R. Hughes - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

Prediction of large-for-gestational-age infants by universal third trimester ultrasound

K. Robertson - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Standard biometric planes: what are the salient anatomical landmarks?

L. Drukker - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Ultrasound prediction of adverse outcome in pregnancies complicated by gestational and pre-existing diabetes mellitus

M. Garbagnati - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

Suloctidil

Effect of false-positive antenatal diagnosis of small for gestational age on prematurity and stillbirth risk

S. Turner - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Customised- versus population-based fetal weight standards to define small for gestational age at 22 weeks of gestation

O. Hugh - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Do some growth-restricted fetuses lose weight?

K. Stephens - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Is estimated fetal weight an accurate representation of birthweight at term?

K. Stephens - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Partial molar pregnancy with co-twin: a successful outcome

A. Banerjee - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Recurrent hydatidiform moles

Levothyroxine

Fetal neurological MRI follow-up in pregnancies with Twin–twin transfusion syndrome treated with fetoscopic laser ablation

J. Sohal-Burnside - International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) , 2020

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Twin–twin transfusion syndrome

N/A

Copyright © 2026. QuantiNova All rights reserved